Ignoring your NASH diagnosis?
About 20% of patients with NASH will advance to NASH with Fibrosis, quickly leading to liver scarring and liver failure
Fatty Liver (NAFLD) is diagnosed as NASH once the liver is inflamed or damaged. Once the inflammation is chronic, then it is considered NASH with Fibrosis.
This study is examining an investigational treatment for patients who suffer from NASH with fibrosis. If you are between 18 to 75 years old and have a NASH diagnosis you could qualify for this clinical research study.
World-class
Medical Oversight
- 24-hour access to MBR’s doctors/medical staff.
- World class medical oversight.
- Free of Charge!
Free of Charge!
- Insurance is NOT required to participate.
- At no cost to you, receive:
– Study related medication
– Fibroscan
– Liver Biopsy
– Physical Exams
– Study related testing
RECEIVE up to
a $1,625 STIPEND
- Those who qualify and choose to participate may receive up to a $1,625 reimbursement.
01
Learn More
Register Today
The first step is to learn more and see if you qualify. After registering, a clinical research coordinator will contact you and answer your questions
Call or text +1 704 283 7359
Visit Our Center
See If You Qualify
Our Address:
343 Venus Street, Monroe NC, 28112
Testimonials
What our Patients say about our services
Research facility
Monroe Biomedical
6300
Square feet Dedicated Research Facility
Cozy
Recreational Area Comfortable Recliners
Fun
Free entertainment options
Friendly
First Class Service from our Nurses and Staff
Free entertainment
High Speed Wifi
Family Friendly
Very Comfortable
Recliners
NASH w/Fibrosis Treatment Study
We are doing this study to learn more about the study drug, cotadutide, and whether it works compared to placebo and is safe, tolerable, and effective in subjects with NASH and liver fibrosis. Cotadutide is expected to lead to weight loss, improve your blood glucose and lipid levels, and improve your liver health. You will administer cotadutide or placebo subcutaneously (into the fatty layer under the skin) daily, using a prefilled pen device. The placebo will look like the study drug, cotadutide, but will not contain any active ingredients.
We are also doing this study to better understand NASH and its associated health problems.
Some parts of this study are experimental, which means not approved by any health authorities, such as the U.S. Food and Drug Administration (FDA), except for use in research studies like this. The untested part of this study is the use of cotadutide in subjects with NASH and liver fibrosis. Cotadutide has been tested in humans in clinical trials with subjects with other diseases, but cotadutide is experimental and is not approved by any health authority yet.
Contact Us
343 Venus Street, Monroe, NC 28112
Office Phone: 704-283-7369
Fax: 704-283-7329
Email: patients@monroeresearch.com
What is NASH disease?
- NASH (Nonalcoholic Steatohepatitis) is a type of liver disease closely related to obesity and metabolic syndrome. NASH is characterized by fat accumulation in the liver, inflammation, and liver cell damage. Over time it could lead to liver failure.
What are the symptoms of NASH disease?
- NASH is often considered a silent disease because it can progress slowly without causing any noticeable symptoms. However, you may experience fatigue, weakness, abdominal pain, and jaundice (yellowing of the skin and eyes). If you are at risk for NASH or have concerns about your liver health, you must talk to one of our doctors and undergo appropriate testing and evaluation. Early diagnosis and intervention are essential for preventing the progression of NASH and its associated complications.
How is NASH disease treated?
- There is currently no approved medication for NASH. Treatment typically involves lifestyle modifications such as weight loss, regular exercise, and dietary changes to manage the underlying conditions contributing to NASH. Early diagnosis and intervention are essential for preventing the progression of NASH and its associated complications. Contact us and participate in our clinical trial to develop new therapies together!
Is NASH disease fatal?
- NASH (Nonalcoholic Steatohepatitis) can lead to severe complications, including cirrhosis (scarring of the liver), liver failure, and liver cancer. In some cases, these complications can be life-threatening. Early diagnosis and intervention are essential for preventing the progression of NASH and its associated complications. Please get in touch with us to find out if you are at risk of the disease.
How much will the study cost?
- There will be zero costs for the participant to take part in the NASH study.
What if I am uninsured?
- Proof of insurance is NOT required to participate in this study. All medical oversight over the course of your study participation is included.
What does investigational medication mean?
- An Investigational medication (also known as investigational new drug) has been approved by the Food and Drug Administration (FDA) for testing in people in a clinical study, but has not been approved for general use, distribution or sale. It is through clinical research that these medications receive full approval by the FDA.
How will I be compensated for participating?
- Participants receive a check following each study visit. For this study, those that qualify and choose to participate could receive a total payment of up to $1,625.